Rapid EGFR Testing With Idylla Alongside NGS Has Potential To Enhance Lung Cancer Patient Health Outcomes

Biocartis NV

25/01/2022 06:05

Jan 25 (Reuters) - Biocartis Group NV  BCART.BR :
    * REG-PRESS RELEASE BIOCARTIS GROUP NV: LARGE UK STUDY SHOWS
RAPID
EGFR TESTING WITH IDYLLA™ ALONGSIDE NGS HAS POTENTIAL TO ENHANCE
LUNG CANCER PATIENT HEALTH OUTCOMES
    * LUNG CANCER ACCOUNTS FOR LARGEST NUMBER OF CANCER DEATHS
WORLDWIDE
    * 102 IDYLLA™ EGFR MUTATION TEST (CE-IVD) RESULTS OF LUNG
ADENOCARCINOMA PATIENTS WERE COMPARED WITH NGS
    * AVERAGE TURNAROUND TIME TO REPORT EGFR MUTATIONS WITH
IDYLLA™
EGFR MUTATION TEST WAS 3.8 DAYS, VERSUS 17 DAYS ON AVERAGE FOR
REPORTING OF NGS RESULTS THROUGH AN EXTERNAL LABORATORY
    * 6 PERCENT OF PATIENTS DIED BEFORE NGS REPORT WAS
AVAILABLE; OF
17 PATIENTS WHOSE CONDITION DETERIORATED RAPIDLY
    * 3 PATIENTS(18 PERCENT) WERE IDENTIFIED AS HAVING AN
ACTIONABLE
VARIANT IN EGFR THAT COULD HAVE BEEN TREATED WITH TYROSINE
KINASE INHIBITORS
    * OF 102 TESTS PERFORMED, AGREEMENT BETWEEN TWO TEST
MODALITIES
WAS ACHIEVED IN 96.4% OF TEST EVENTS WHERE THERE WAS SUFFICIENT
TISSUE FOR TESTING

Source text for Eikon:  ID:nGNE7zZ9h 
Further company coverage:  BCART.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))